Kalaris Announces ASRS TH103 Phase 1a Data Presentation

Key Takeaways

• Kalaris said it will present Phase 1a first-in-human TH103 data in treatment-naïve neovascular AMD at the 2026 ASRS meeting.
• Kalaris said the Phase 1b/2 multiple ascending dose study in neovascular AMD is actively enrolling and dosing, with initial data expected in 1H 2027.
• Kalaris describes TH103 as an investigational dual-targeting VEGF/HSPG biologic designed for intravitreal delivery.

Kalaris Therapeutics said Phase 1a TH103 data will be presented at the ASRS 2026 Annual Meeting on Friday, July 17, 2026, at 8:00 am EDT in Montréal. The company also said its Phase 1b/2 neovascular age-related macular degeneration study is actively enrolling participants and administering study treatment. The presentation brings a first-in-human update to retina specialists at the annual meeting while the multidose program continues in parallel clinical development.

The presentation describes a first-in-human evaluation of TH103 as a novel dual-targeting VEGF and HSPG biologic in treatment-naïve neovascular AMD. Kalaris says the presentation covers a Phase 1 single ascending dose study in treatment-naïve patients with neovascular age-related macular degeneration. Joel Pearlman, MD, PhD, of Retinal Consultants Medical Group is listed as the presenter for the session. The program places it within an AMD symposium addressing new targets, emerging therapies, and early clinical results in nAMD. This scheduled conference appearance appears to be the nearest public milestone in the company’s current update.

Kalaris also says its ongoing Phase 1b/2 program is a multiple ascending dose study in neovascular age-related macular degeneration. The company reported continued enrollment and dosing as the study advances through early clinical development in patients with nAMD. Kalaris also said it remains on track to report initial data during the first half of 2027. According to the company, that first readout is intended to accelerate TH103 development and help inform dose selection for potential future Phase 3 planning. The next stated milestone for the multidose program is the planned 1H 2027 data update.

Kalaris describes TH103 as an investigational dual-targeting biologic designed for intravitreal delivery, with potential applications in exudative or neovascular retinal diseases. The company says the molecule was engineered by Dr. Napoleone Ferrara with optimized binding to VEGF receptor 1 ligands. Its description also includes concurrent heparan sulfate proteoglycan anchoring as part of the proposed design. Potential applications named by Kalaris include wet AMD, diabetic eye disease, and retinal vein occlusion. Kalaris positions the program within its broader clinical-stage effort to develop and commercialize treatments for prevalent retinal diseases.